Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

DAWN·NASDAQ

$21.53

+0.0000%
HealthcareBiotechnology

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

At a Glance

Live Snapshot
Market Cap$2.22B
EPS-1.0400
P/E Ratio-20.70
Earnings Date05/13/2026

dawn

Depreciation and Amortization

Last Annual Value

3.48M

3-Year CAGR

87%

5-Year CAGR

86%

10-Year CAGR

%

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. Competitors Analysis of Depreciation and Amortization

DAWN · NASDAQ
CompanyDepreciation and Amortization
CAGR 3Y
CAGR 5Y
CAGR 10Y
3.48M
108.6%77.2%N/A 
1.20M
5.2%9.0%31.0%
0.00
N/AN/AN/A
546.00K
15.6%31.3%N/A
-3.03M
N/AN/AN/A
ARVN logo
Arvinas, Inc.
NASDAQ:ARVN
5.20M
-8.1%-2.8%28.1%
ERAS logo
Erasca, Inc.
NASDAQ:ERAS
3.11M
-5.9%30.2%N/A
21.15M
2.8%29.5%N/A
3.50M
12.7%15.4%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
31.00K
1.1%19.0%-27.3%
Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. Fair Value Envelope

DAWN · NASDAQ

Our analysis suggests that DAWN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $21.53, this represents a potential HIDDEN relative to our calculated worth for Day One Biopharmaceuticals, Inc..

Intrinsic Value
Current Price: $21.53